Akebia Therapeutics (AKBA) Research & Development (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Research & Development data on file, last reported at $14.8 million in Q1 2026.

• Research & Development for Q1 2026 came in at $14.8 million, up 51.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $41.8 million (up 10.86% YoY), and the FY2025 annual result was $62.4 million, up 65.62% from the prior year.
• Research & Development improved to $14.8 million in Q1 2026 per AKBA's latest filing, from $1.0 million in the prior quarter.
• Over five years, Research & Development peaked at $43.8 million in Q1 2022 and troughed at $1.0 million in Q4 2025.
• A 5-year average of $16.6 million and a median of $13.3 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 767.57% in 2022, then plunged 91.52% in 2025.
• A 5-year view of Research & Development shows it stood at $32.1 million in 2022, then sank by 69.27% to $9.9 million in 2023, then rose by 19.47% to $11.8 million in 2024, then sank by 91.52% to $1.0 million in 2025, then soared by 1380.7% to $14.8 million in 2026.
• Business Quant data shows AKBA's Research & Development at $14.8 million in Q1 2026, $1.0 million in Q4 2025, and $14.9 million in Q3 2025.